PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity

Immunotherapy, in the form of hematopoietic stem cell transplantation (HSCT), has been part of the standard of care in the treatment of acute leukemia for over 40 years. Trials evaluating novel immunotherapeutic approaches, such as targeting the programmed death-1 (PD-1) pathway, have unfortunately...

Descripción completa

Detalles Bibliográficos
Autores principales: Koller, Paul, Baran, Natalia, Harutyunyan, Karine, Cavazos, Antonio, Mallampati, Saradhi, Chin, Renee L, Jiang, Zhou, Sun, Xian, Lee, Heng-Huan, Hsu, Jennifer L, Williams, Patrick, Huang, Xuelin, Curran, Michael A, Hung, Mien-Chie, Konopleva, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551962/
https://www.ncbi.nlm.nih.gov/pubmed/37793852
http://dx.doi.org/10.1136/jitc-2022-006619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551962/
https://www.ncbi.nlm.nih.gov/pubmed/37793852
http://dx.doi.org/10.1136/jitc-2022-006619

Ejemplares similares